Evaluate Saxagliptin in Adult Indian Patients With Type 2 Diabetes Inadequate Glycemic Control
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Deborah Price, MSc
AstraZeneca, Wilmington, USA
Study Chair - Peter Ohman, MD, PhD
AstraZeneca, Wilmington, USA
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Gujarat, Ahmedabad, India
- Research Site
Karnataka, Bangalore, India
- Research Site
Tamil Nadu, Chennai, India
- Research Site
Tamil Nadu, Coimbatore, India
- Research Site
Andhra Pradesh, Hyderabad, India
- Research Site
Madhya Pradesh, Indore, India
- Research Site
Haryāna, Karnal, India
- Research Site
Kerala, Kochi, India
- Research Site
Maharashtra, Pune, India
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2009
- Primary completion
- 31 Jul 2010
- Completion
- 31 Jul 2010
- Last update posted
- 26 Sept 2011
- Registered enrollment
- 213
- Registry id
- NCT00918879
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.